Monoclonal antibodies (MAbs) directed against phase I and II variants of Coxiella burnetii were produced by fusing myeloma SP2/0-AG 14 cells with spleen cells from mice immunized with the chloroform-methanol extraction residue of phase I whole cells. Two hybridoma clones which distinguished the phase variants by microimmunofluorescence assay were isolated and characterized. The MAbs showing specificity for phase I cells (MAbI-1, immunoglobulin G, subclass 3K) reacted with the hot phenol-water extract of phase I C. burnetii in immunodiffusion and enzyme-linked immunosorbent assays. MAbI-1 reacted with highmolecular-weight components from phase I phenol-water extract and whole cell in an immunoblot assay. Specificity of MAbI-1 for a carbohydrate epitope in the phenol-water extract was demonstrated by periodic acid inactivation of binding by a competitive enzyme-linked immunosorbent assay. Phase I antigenic sites were apparently well represented on the surface of cells as demonstrated by complete fluorescence and microagglutination. The MAb showing specificity for phase II celis (MAbII-1, immunoglobulin G, subclass 2bK) reacted with whole cells in the microimmunofluorescence assay, microagglutination test, complement fixation test, and the enzyme-linked immunosorbent assay. MAbII-1 reacted specifically with a 29,500-dalton surface protein as demonstrated by immunoprecipitation of 1251-surface-labeled cells. Although MAbII-1 reacted with detergent-solubilized protein, it did not react with sodium-dodecyl sulfate-denatured protein by immunoblot assay. This protein was not exposed on the surface of phase I cells, but chloroformmethanol extraction of phase I cells exposed the phase II epitope.
Coxiella burnetii is the etiological agent of Q fever with major clinical importance in humans at risk in enzootic communities (2) . This rickettsia is generally isolated from infected tissues by injection of tissue homogenates into guinea pigs or mice (1) . Microorganisms recovered from the spleens of immunocompetent animals have been described serologically as phase. I (31-33) . Upon serial passage of phase I cells in the yolk sac of fertile hen eggs, phase II is detected (19, 32) . The phase variants isolated from yolk sacs exhibit both immunological and biological differences (reviewed in references 3, 38, and 39). Detection of these phase variants has relied upon serological techniques which require the production of specific antigen used to titrate phasespecific antibody produced during the infection or vaccination of guinea pigs, mice, or rabbits (10) (11) (12) . Infection or vaccination with phase I C. burnetii elicits early anti-phase II and late anti-phase I antibody responses (10) (11) (12) , whereas C. burnetii in phase II gives rise to only anti-phase II antibodies. Thus, the immunogens representing the phase variants are important antigenic markers of C. burnetii infection and vaccination.
Phase I to II variation seems to correlate with smooth (S) to rough (R) (S-R) lipopolysaccharide (LPS) changes (19, 30) . Attempts to detect phase-specific antigens by using polyclonal antibodies (17) and cytochemical techniques (7, 21) have met with limited success. Thus, in an attempt to prepare reagents that distinguish subtle antigenic variations between the phase variants, we turned to the immunological specificity exhibited by monoclonal antibodies (MAbs) (21) .
As an extension of our investigation on the molecular heterogeneity of C. burnetii antigenic determinants which correlate with phase variation, we prepared two hybridomaderived antibodies, one against phase I cells and one against phase II cells. In the present report, we characterize the MAbs as to their specificity for membrane determinants of cloned isogenic pairs of phase variants derived from C. burnetii 9 Mile (phases I and II) and C. burnetii Ohio (phase I) isolates.
MATERIALS AND MIETHODS Bacteria and antigens. C. burnetii isolates used were phases I and II prepared as previously described (39) . C. burnetii isolates were 9 Mile phase I, clone 7, (CB9MIC7); 9 Mile phase II, clone 4 (CB9MIIC4); and Ohio phase I (CBOI) (39) . B3acteria were purified, inactivated with 1% formaldehyde, dialyzed against demineralized glass-distilled sterile water, and lyophilized (39) . Chloroform-methanol (CM) extraction of CBOI was done as previously described (38) . CM residue (CMR) produced by CM extraction was used to immunize mice. CMR suspensions were prepared in phosphate-buffered saline (pH 7.2) (39) for immunization of mice (38) . Phenol-water extracts (PWE) were prepared from phase I organisms by the method of Westphal and Jann (36 (21) . Antibody production and pathological changes have been established in another study (38) .
Generation of hybridomas. Hybrids of the myeloma SP2/ O-AG 14 cells, kindly provided by Gregory A. Dasch (Naval Medical Research Institute, Bethesda, Md.) and BALB/c mouse spleen cells were generated by standard procedures (20, 21) . Single-cell suspensions were prepared from immune spleens excised 48 h after the last 50-pLg dose of CMR and were fused with myeloma cells by polyethylene glycol (20, 21) . Hybrids were plated in 24-well tissue culture plates in RPMI medium containing 10% fetal calf serum, and 48 h elapsed before the addition of hypoxanthine-aminopterinthymidine medium. Microcultures showing cell growth were sampled and tested for antibodies to the immunizing and cross-reacting phase I or II antigens. Antibody-forming hybridomas in each fusion experiment were cloned by limiting dilution by using 5 x 10 normal spleen cells per ml as feeder cells. Attempts to establish hybridoma cells intraperitoneally in BALB/c mice previously treated with 2,6,10,14-tetramethylpentadecane (pristane; Aldrich Chemical Co., Inc., Milwaukee, Wis.) were not successful. There Organisms were surface labeled with 1251 by using lactoperoxidase as previously described (37) . Cells (10 mg [dry weight]) were solubilized in 1 ml of lysing buffer (0.02 M Tris hydrochloride in 0.85% saline [pH 7.4]-0.1% SDS-0.1% deoxycholic acid-2.0% Triton X-100-10 mM EDTA-0.02% NaN3) for 30 min at 37°C. The soluble extract was prepared by centrifugation at 100,000 x g for 30 min at 30°C. This high-speed supernatant (lysate) was used as the source of 12fI-surface-labeled proteins. Radioimmunoprecipitation (RIP) was carried out by incubation of a 1:6 dilution of lysate with MAbI-1 or MAbII-1 for 30 min at room temperature. Protein A-Sepharose CL-4B (20 ,ug) was added, and incubation continued for an additional 30 min. The complex was washed three times in NET buffer with Microfuge B (Beckman Instruments, Inc., Fullerton, Calif.). Samples were suspended in Laemmli sample buffer containing 1.53% dithiothreitol and then subjected to SDS-PAGE (see above). A comparison of the antigens was done in the above tests with the respective MAbs.
Periodic acid treatment of PWE. PWE from phase I C. burnetii cells was used before and after proteinase K (PK) digestion (9) . PWE (45 mg) was treated with 10 mg of PK in saline containing 1% SDS at 37°C for 16 h and at 56°C for 1 h. This suspension was extracted with hot phenol (36) . PWE and PWE treated with PK (PWE-PK), 450 ,ug each, were treated with 0.1 M periodic acid in 0.5 M acetic acid at 4°C for 24 h. Ethylene glycol was added to stop the reaction. Treated and untreated PWEs were used in the antigencompetition ELISA and immunodiffusion assay.
Antigen-competition ELISA. Microplate wells (Immulon I; Dynatech Laboratories, Inc., Alexandria, Va.) were coated with 100 RI (312 ng) of PWE from phase I C. burnetii cells (Williams et al., in preparation). Excess antigen was removed by washing the wells with 0.01 M phosphate-buffered saline (pH 7.4) containing 0.05% Tween 20. Periodic acidtreated and untreated PWEs at various concentrations were incubated with MAbI-1 for 16 h at 4°C in glass tubes. The antigen-absorbed MAbI-1 was used directly in the ELISA. The data are expressed as percent of unabsorbed MAbI-1 (see Fig. 4 ).
RESULTS
Development and selection of hybridomas. Previous studies of phase I C. burnetii whole-cell and CMR vaccines indicated that immunosuppression with severe pathology as measured by splenomegaly, hepatomegaly. and death of mice occurred with whole-cell vaccines but not with CMR vaccines (38) . The antibody responses in mice were similar with both vaccines. In the present study, the CMR vaccine was , 100, and 1,000 ,ug/ml, respectively. (E to H) Phase 11 antigen was used at 100, 100, 1,000, and 100 ,ug/ ml, respectively. Antigens were combined with hyperimmune I sera (A and E), hyperimmune 11 sera (B and F), MAbl-1 TCF (C and G), and was compared with that of hyperimmune I and II sera. The hyperimmune sera reacted with all of the antigens, whereas the phase I (MAbI-1) and phase II (MAbII-1) MAb fluorescence gave a pattern of specific whole-cell staining, and no cross-reactions were noted ( Fig. 1 and 2 ). Each MAb reacted with the CMR immunizing antigen, but each reacted specifically with the respective phases (I or II) of C. burnetii. Interestingly, MAbII-1 reacted with what appeared to be aggregates or clumps of CMR antigen (Fig. 2H) , whereas hyperimmune II sera reacted with clumped antigen and individual cells (Fig. 2F) . Specific membrane fluorescence with MAbs and viable cells was also demonstrated (data not shown). Thus, these two MAbs reacted with viable and killed bacteria. The MAbs were successfully cloned, expanded, and recloned before characterization was attempted.
Isotypes of MAb. Immunoglobulin classes of hybridoma antibodies were determined by double immunodiffusion with specific sera (data not shown). MAbI-1 precipitated with anti-immunoglobulin G (IgG) subclass 3 (IgG3) monospecific for the heavy chain, MAbII-1 precipitated with anti-IgG2b (IgH) monospecific for the heavy chain, and both MAbs reacted with anti-mouse K (light chain specific). Neither MAb reacted with anti-mouse IgG2a, IgE, X, IgD, IgM, IgGl, or IgA.
Specificity of the MAbI-1 and MAbII-l in serological assays. The MAbs were tested in a series of serological tests routinely used in diagnostic laboratories for detection of C. burnetii infection (Q fever) or vaccination. Isogenic pairs of CB9MIC7 and CB9MIIC4 were used in microagglutination CF, IFA, and ELISA tests to evaluate the reactivity of MAbI-1 and MAbII-1 ( (Fig. 3) . Immunoprecipitates were formed between PWE and MAbI-1 (ascites and TCF) and hyperimmune guinea pig anti-phase I whole cells from Ohio and 9 Mile isolates. Treatment of phase I PWE with periodic acid prevented the formation of immunoprecipitates with MAbI-1 (data not shown). By using the competitive ELISA with PWE as the solid-phase antigen, the determination of absorption reactivities of MAbI-1 was tested. Treatment of PWE or PWE-PK with periodic acid prevented the absorption of MAbI-1 activity, whereas untreated antigen absorbed the monoclonal antibody (Fig. 4) . Thus, MAbI-1 recognized a carbohydrate epitope specificity present in the PWE.
Reactivity of MAbI-I and MAbII-l in immunoblot and RIP
assays. Immunoblotting phase I (whole cells or PWE) or phase II antigens indicated that MAbI-1 reacted with highmolecular-weight components in both phase I antigens (Fig.  SB, lanes 2 and 3) . In contrast, no binding activity of MAbI-1 was detected with the phase II whole cells (Fig. SB, lane 4) .
Attempts by immunoblotting to demonstrate binding activity with MAbII-1 were unsuccessful (Fig. SC, lanes 2, 3, and 4) ; however, by RIP assay with 1251-surface-labeled phase I and II whole cells, a 29,500-dalton binding was detected with only phase II cells (Fig. SD, lane 4) . RIP assay with MAbI-1 and PWE from phase I cells followed by silver staining (35) indicated that polysaccharides of high and low molecular weights were precipitated (data not shown). Thus, confirming the periodate oxidation experiment (above), MAbI-1 reacted with carbohydrate-containing epitopes in the PWE from phase I whole cells, whereas MAbII-l reacted with a 29,500-dalton surface protein antigen from phase II cells.
DISCUSSION
Analysis of antigenic surface components of C. burnetii was undertaken by developing MAbs which distinguish phase I and phase II variants. In this study, we used phase I CMR immunizing antigen because previous investigations indicated that this vaccine induced significant antibody levels but did not induce deleterious tissue reactions (38) or lymphocyte unresponsiveness in mice (T. A. Damrow and J. C. Williams, manuscript in preparation). We rationalized that the use of CMR in immunization protocols would allow an analysis of phase-specific determinants, since high levels of phase I and phase II antibodies were detected in the sera of mice (38) . In this study, we showed that CM extraction of phase I cells exposed MAbII-1-reactive antigenic sites which are normally inaccessible to antibodies, but which are exposed on the surface of phase II cells.
The phase variants of C. burnetii seem to have some of the characteristics of S-R LPS mutational variation described for Salmonella spp. and related members of the family Enterobacteriaceae (20, 24) . Thus, it was not surprising that MAbI-1 recognized a component in the PWE from phase I cells. Isolation of LPS by PW extraction followed by PK treatment suggested that MAbI-1 recognized a carbohydrate determinant. The carbohydrate nature of MAb-1 recognition was verified by using periodic acid-treated PWE in a competitive ELISA (Fig. 4) . MAbI-1 did not bind to periodic acid-treated PWE (Fig. 4) or to phase II whole cells (Table  2) ; however, MAbI-1 was absorbed by untreated PWE (Fig.  4) and by phase I whole cells (Table 2 ). This epitope may be associated with phase I LPS; however, this point requires further investigation. The antigenic determinants on the surface of phase I cells appear to be evenly distributed since agglutination (Table 1) and complete whole-cell fluorescence ( Fig. 1 and 2 ) were obtained; however, MAb-1 did not activate complement in our standard CF assay, which is consistent with its IgG3 isotype (15, 28) . Recently, we have isolated four more IgG3 MAbs which recognize carbohydrate determinants in PWEs. These MAbs should facilitate structural studies of the phase I cell wall carbohydratecontaining antigen(s) with the objective of characterizing the chemical structure of polysaccharide-and LPS-specific antigenic determinants of S-R LPS transition (30) . Also, LPSspecific MAbs should facilitate the determination of serological specificity of different polysaccharide fractions while providing information on the cell wall LPS-associated proteins (5, 27) Fig. 1 and 2 ). MAbII-1 performed as an agglutinating antibody; it gave complete whole-cell fluorescence of phase II cells, and it activated complement in our standard CF assay. Studies with RIP assays suggested that MAbII-1 recognized a 29,500-dalton surface protein which was not accessible on the surface of phase I cells (Fig. 5) . MAbII-1 is the only MAb isolated by us which shows phase II specificity. Perhaps other MAblIs will be isolated in the future which recognize new components or new epitopes on the 29,500-dalton protein.
Virulent and avirulent C. burnetii are represented by phase I and II cells, respectively (8, 10, 13, 25) . C. burnetii in phase I or II are highly successful obligate intracellular parasites (3, 26) which are activated to metabolize and replicate in the phagolysosome (6, 16 (5, 27) . The mutational S-R variation in Escherichia coli and Salmonella typhimurium is also correlated with the virulent (S) to avirulent (R) transition (18) . Less attention has been focused on the surface-exposed proteins of C. burnetii during phase variation. In another study, changes in the mosaic of surface-exposed proteins which accompany a reduction in virulence have been noted for C. burnetii (J. C. Williams and S. Stewart, manuscript in preparation). In the present study, we did not know whether the 29,500-dalton protein was a target of a protective immune response. The emergence of new antigenic and perhaps physiologically important proteins may lead to the development of attenuation in phase II C. burnetii. Moreover, pathogenicity of C. burnetii appears to be linked to the expression of LPS (8, 10, 13, 25) and certain components removed by CM (36) 
